About
Shane Schaffer is the co-founder, Chairman, and CEO of Cingulate Therapeutics, based in Kansas City, Kansas. This Phase 3 clinical-stage biopharmaceutical company is dedicated to developing and managing innovative next-generation pharmaceutical products, mainly targeting Attention Deficit/Hyperactivity Disorders (ADHD), along with anxiety disorders and insomnia. A seasoned professional with 25 years in the pharmaceutical industry, he specializes in drug development and commercialization. His leadership and entrepreneurial skills have been instrumental in various business areas, including product launches, brand planning, joint venture brand management, life cycle management, and market development, establishing him as a notable figure in biopharmaceutical and marketing.
Work
Cingulate Inc.